- [Controversies in the management of type 2 diabetes]
Apothekerin und freie Medizinjournalistin, Wegscheiderstrasse, Halle, Saale
Med Monatsschr Pharm 36:463-7. 2013
..However, the contributing medical associations could not agree on some questions. Above all, there is a dissent which drug to choose, if metformin cannot be used or does not suffice in monotherapy...
- [Common errors in blood pressure monitoring]
Med Monatsschr Pharm 36:320-3. 2013
..However, the results are only reliable if some rules are observed. These are mainly related to the right choice of devices, execution of the monitoring as well as documentation and assessment of the measurement...
- [Prevention, diagnosis and therapy of the diabetic foot]
Med Monatsschr Pharm 36:292-6; quiz 297-8. 2013
..If ulcerations are not treated appropriately, amputations might become necessary. But these can be averted by a complex strategy of preventive measures, early diagnosis and sufficient treatment...
- [Dapagliflozin. Lowering blood glucose levels by increasing glucosuria]
Med Monatsschr Pharm 36:128-32. 2013
..Especially bladder cancer could be observed. However, the increase of cancer cases was not statistically significant. In contrast to the European Medicines Agency, the FDA has not yet approved dapagliflozin for safety reasons...
- [Healthy nutrition in pregnancy]
Med Monatsschr Pharm 36:65-7. 2013
..Recent recommendations emphasize the intake of folic acid and iodide. The reader also obtains advice about the extent of weight gain, avoidance of alcohol and tobacco smoke and how to prevent food-borne infections...
- [Surgery against diabetes?]
Med Monatsschr Pharm 35:410-5. 2012
..issues have not been clarified by clinical trials so far: Which patients benefit the most? How sustainable is a diabetes remission induced by surgery? And how serious are metabolic and psychiatric side effects of the surgical procedures?..
- [New targets in type 2 diabetes therapy]
Med Monatsschr Pharm 33:280-4. 2010
..The forthcoming years will show which of the drugs in clinical trials will get marketing authorization...
- [Vernakalant--a new drug for pharmacological conversion of atrial fibrillation]
Med Monatsschr Pharm 34:154-8. 2011
..Clinical trials showed conversion rates of about 50% which is comparable to other antiarrhythmic drugs. Further trials will show if vernakalant is less pro-arrythmogenic than its competitors...
- [Ticagrelor: a novel antiplatelet agent for patients with acute coronary syndrome]
Med Monatsschr Pharm 34:226-32. 2011
..In clinical trials the antiplatelet agent reduced significantly vascular mortality and death from any cause when compared to clopidogrel in patients with acute coronary syndrome...